Short answer
Tonix Pharmaceuticals Holding Corp. (TNXP) filed an 8-K current report with the SEC on May 15, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Boilerplate Regulation FD disclaimer only; no substantive company disclosure.
Tonix Pharmaceuticals Holding Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Boilerplate Regulation FD disclaimer only; no substantive company disclosure
- No investor-actionable operating, financial, financing, or strategic information in the provided text
Item 8.01 · Other Events
- TNX-4800 Phase 1 pharmacokinetic simulations support a two-dose 350 mg subcutaneous regimen
- Predicted serum levels above 10 µg/mL for 196 days, exceeding the proposed six-month primary endpoint
- Proposed adaptive Phase 2 field study targeted for first half of 2027, pending FDA agreement
- Simulated MEC durations: 20 µg/mL for 136 days, 15 µg/mL for 161 days, and 5 µg/mL for 265 days
- Findings remain predictive and require FDA alignment plus Phase 2 validation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tonix Pharmaceuticals Holding Corp. 8-K filings
Get the next TNXP 8-K as it lands
Follow TNXP for push alerts, or ask the research agent what this filing means.